I too question myself if I am missing something regularly, but like you I can’t find anything. Sure maybe I’m overly optimistic about cancer, combo launch, etc. but even if wrong I can’t see being so wrong where this stock won’t be significantly higher than our current share price. I run the numbers only based on combo approval and even licensed at 15% and fully diluted to 700M shares, with a normal valuation of 4 P/S or 10-15 PE we are worth multiples of where we currently trade. If/once anything else is successful and our financial concerns cleared up the valuation multiplies exponentially.
I think once we are able to uplist that will change everything. I truly believe that the word is not out and analysts coverage and institutional buyers will change that. Obviously we have a ways to go to be uplist eligible (organically I hope), but that time is coming pretty soon. This should be a fun ride for a few years once we crack the code.
(1)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.